These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29019869)

  • 1. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
    Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
    Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
    Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma.
    Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM
    J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary.
    Ota T; Clayton AC; Minot DM; Shridhar V; Hartmann LC; Gilks CB; Chien JR
    Mod Pathol; 2011 Feb; 24(2):277-87. PubMed ID: 21076460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation.
    Ono T; Kishimoto K; Tajima S; Maeda I; Takagi M; Suzuki N; Mimura H
    Acta Radiol; 2020 Jul; 61(7):992-1000. PubMed ID: 31698924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
    Itamochi H; Kigawa J; Terakawa N
    Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
    Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
    Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
    Miao Y; Cai B; Liu L; Yang Y; Wan X
    Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
    Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
    Liu P; Sun YL; Du J; Hou XS; Meng H
    Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.